Pulmonology, Respiratory and Sleep Medicine: Industry Report

Summary

Chronic respiratory diseases (CRDs) are a major global health burden. The latest available analysis estimates nearly 570 million people living with a CRD ², and WHO states that COPD and asthma together affect over half a billion people ³. COPD is projected to rise by 23% globally ⁴. Sleep-disordered breathing adds further demand, but estimates are wide: obstructive sleep apnoea (OSA) prevalence ranges from 730 million to 936 million adults aged 30 to 69 ⁷. Workforce data show pulmonology among the most in-demand specialties, with 73% of US pulmonologists aged 55 or older ¹⁰, while a national projection shows high supply adequacy ¹². Principal risks are workforce ageing, geographic access gaps, very limited market, reimbursement and cost data, and uneven evidence on digital tools. The outlook points to rising demand, and stakeholders need better data on capacity, cost and outcomes before making firm investment or planning decisions.

Key findings

1. 1

   Over half a billion people live with COPD or asthma

   WHO states that COPD and asthma, the most common chronic respiratory diseases, together affect over half a billion people. This is a verified official statistic with a global scope.

   Confidence: High
2. 2

   COPD demand is projected to rise

   COPD cases are projected to increase by 23% globally, with women and people in low- and middle-income countries more affected. This is a forecast, not an observed trend.

   Confidence: Medium
3. 3

   Sleep apnoea burden is large but highly uncertain

   Global OSA estimates for adults aged 30 to 69 range from 730 million to 936 million. The pooled prevalence of 54% in a separate meta-analysis was rated very low certainty by GRADE criteria, so sleep demand cannot be sized reliably.

   Confidence: Medium
4. 4

   Pulmonologists are among the most in-demand specialists

   A recruiting firm reports that pulmonologists are the most in-demand specialists it recruits, and that 73% of pulmonologists are aged 55 or older. This is a vendor source reported secondhand, so it indicates direction rather than precise scale.

   Confidence: Qualitative
5. 5

   National adequacy projections are high but disputed in detail

   HRSA projects critical care and pulmonology supply adequacy of 112%, and a peer-reviewed model reports 99.5% in the latest period rising to 110% later. The gap between these figures reflects differing models and definitions.

   Confidence: Medium
6. 6

   Access to pulmonologists is uneven across US geographies

   About 7% of urban-cluster adults and 5% of rural adults lacked access to a pulmonologist within 50 miles in a national study. The study period is not stated in the excerpt.

   Confidence: Medium

11. Industry definition and scope

This report covers pulmonology, respiratory medicine and sleep medicine as a clinical specialty and service line. It includes the diagnosis, treatment and long-term management of chronic respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD) ²⁶, and sleep-disordered breathing, chiefly obstructive sleep apnoea (OSA) ⁷. The geographic scope is global, with US and WHO European Region examples for workforce and access.

Terminology is not consistent across sources. The Global Burden of Disease analysis counts chronic respiratory diseases as a group and ranks them fourth among causes of death ¹. A Lancet review ranks COPD alone as the third cause of death worldwide ⁶. These rankings cover different scopes and should not be combined.

OSA estimates depend on the diagnostic threshold. The main prevalence figures use an apnoea-hypopnoea index of 5 or more events per hour ⁷. Market revenue, reimbursement and sleep testing volumes fall outside the verified evidence and are treated as data gaps.

Definitions are taken as stated by each source. No single harmonized definition exists in the pack.

22. Market size, structure and value chain

No verified global market size or revenue figure for pulmonology devices, drugs or services was found in the source pack, so this report does not estimate market value. The best available proxy for scale is epidemiological demand. Nearly 570 million people were living with a chronic respiratory disease in the latest available analysis ², and asthma accounted for an estimated 363 million of these cases ².

In the WHO European Region, 81.7 million people are affected by CRDs, and economic loss is estimated at approximately US$ 21 billion annually ⁴. This is an estimate from a WHO regional report. It is not a market size, and the pack does not break the figure down by cost category.

Service volume can be approached through exacerbations. Global COPD-related exacerbations are projected at 456.4 million annually at an earlier projection point and 567.6 million at a later one ⁵. These are forecasts from a peer-reviewed model.

The value chain is not documented in detail in the pack. Stakeholders that appear in the sources include patients, specialist clinicians, health systems, public health agencies, workforce planners and recruiting firms ⁴¹⁰¹². Revenue models such as fee-for-service, capitation, device sales and drug sales are not verified for this specialty, and the pack does not confirm the shares of public, private or community providers.

• People living with a chronic respiratory disease Nearly 570million people Observed Global, Latest available data [2]

Market value is excluded because no verified comparable figures exist in the pack.

33. Customers, demand and adoption

Demand is driven by population ageing, rising COPD incidence and risk factors. A recruiting firm links the demand for pulmonologists to population ageing and rising COPD ¹⁰. The Global Burden of Disease analysis identifies tobacco use, air pollution and healthcare access as influences on the prevalence of CRDs, which vary considerably by region ¹.

COPD demand is projected to grow, with a 23% increase in cases forecast globally and a larger effect on women and people in low- and middle-income countries ⁴. This is a WHO forecast and should be read as a projection, not an observed trend.

Sleep medicine demand is highly uncertain. A logistic model estimated 730 million adults aged 30 to 69 with OSA, while a country-imputation algorithm estimated 936 million and suggested the logistic model may understate burden ⁷. A systematic review of older adults estimated 35.1% prevalence, with the highest figure in the Americas at 41.9% ⁸. A separate meta-analysis pooled prevalence at 54%, but rated the certainty of this evidence very low ⁹.

Adoption of sleep testing, CPAP and inhaled therapies is not verified in the pack, and purchasing criteria for patients, payers or providers are not documented. Customer expectations and equity outcomes by income group were also not verified.

Prevalence values are estimates and differ by method, threshold and age range.

44. Competitive landscape and key players

The pack does not provide market shares, revenue rankings or supplier concentration data for pulmonology. Competitive comparison is therefore limited to provider types and evidence producers rather than commercial rivals.

A recruiting firm, Merritt Hawkins Associates, reports that pulmonologists are the most in-demand specialists it recruits ¹⁰. The report is a vendor source, reported through the American Academy of Sleep Medicine, and its publication timing should be checked against the original. Its findings show recruiting competition for specialists, but they do not measure provider market position.

A vendor-sourced TelePulmonology document and a ResMed-issued release are in the pack but are excluded from this analysis. The TelePulmonology figures are unverified, and the ResMed figure is vendor-sourced and superseded by peer-reviewed analysis ⁷. These sources are not treated as evidence of competitive position.

Public, private and community providers cannot be compared on volumes, waiting times or costs, because the pack contains no source that makes this comparison. Comparable company examples were limited in the pack. Readers should treat any competitive conclusions as provisional until provider-level data are available.

Vendor claims are reported with their source type and are not used as primary evidence.

55. Technology, operations and workforce

The workforce is ageing. A recruiting firm reports that 73% of US pulmonologists are aged 55 or older, a higher share than across physicians overall ¹⁰. This signals a retirement pressure, but the age profile alone does not show whether capacity is short.

HRSA projects supply adequacy of 112% for critical care and pulmonology medicine, among the highest of specialties ¹². A peer-reviewed model reports workforce adequacy of 99.5% in the latest period, projected at 110% later ¹¹. These figures disagree in level, so the national picture should be treated as unsettled. The combined shortage of 158,990 full-time equivalent physicians in HRSA's projection covers all specialties reporting shortages and is not specific to pulmonology ¹².

Paediatric pulmonology capacity has grown. Mean paediatric pulmonologist availability by hospital referral region rose from 0.62 to 0.98 per 100,000 children, with exact years not stated in the excerpt ¹³.

Digital health adoption is only partly verified. Telepulmonology, remote monitoring and AI spirometry rest on a non-authoritative source and a patent document, not on peer-reviewed outcome evidence . These approaches should be classed as emerging or experimental until stronger evidence is available. Established practice is the conventional care of asthma, COPD and OSA, though the pack does not describe its protocols in detail.

• Projected supply adequacy, critical care and pulmonology 112percent Forecast United States, Projected, latest available data [12]

Workforce projections depend on model assumptions, and the two sources use different levels and dates.

66. Regulation, standards, risk and sustainability

The pack contains no binding regulation, reimbursement rule or clinical standard specific to pulmonology in any jurisdiction. The regulatory position is therefore not verified here, and nothing in this report should be read as legal or regulatory advice. The WHO and WHO Regional Office for Europe sources are official statistical and policy publications, not binding rules ³⁴.

Environmental and social factors carry significant weight. Tobacco use and air pollution are named as drivers of regional variation in CRDs ¹. The WHO European Region spotlight, developed with the European Respiratory Society, focuses on health equity in COPD and asthma ⁴.

Economic burden is substantial but estimated. CRDs in the WHO European Region are estimated to cost approximately US$ 21 billion annually ⁴. This figure is an estimate and the components are not broken down in the excerpt.

Evidence risk is material. The OSA pooled prevalence of 54% is rated very low certainty ⁹, and the 936 million OSA figure rests on imputation ⁷. Patient privacy and data protection requirements for sleep and respiratory records are not addressed in the pack. Nothing in this section constitutes medical advice for individuals.

• Estimated annual economic loss from CRDs, WHO European Region 21US$ billion per year Estimate WHO European Region, Annual, latest available data [4]

Binding requirements, proposals and voluntary guidance are not separated in the pack because no regulatory source was retrieved.

77. Challenges, opportunities and case examples

The main constraints are rising demand, an ageing specialist workforce and uneven access. Demand is projected to rise ⁴⁵, and a national US study found that about 7% of urban-cluster adults and 5% of rural adults lacked access to a pulmonologist within 50 miles ¹⁴. The study period is not stated in the excerpt, so the figures describe access at an unknown point.

Opportunities exist in workforce growth and in data-driven planning. Paediatric pulmonology availability rose across US hospital referral regions ¹³. Digital tools may widen reach, but their benefit is not yet established by peer-reviewed outcome evidence in the pack.

Case example 1: US paediatric pulmonology. Availability rose from 0.62 to 0.98 per 100,000 children, showing that targeted workforce growth can be measured ¹³. Case example 2: the WHO Regional Office for Europe, with the European Respiratory Society, published a health equity spotlight on COPD and asthma across the European Region ⁴, which provides a regional benchmark for equity analysis. Case example 3: a recruiting firm reports strong demand for pulmonologists ¹⁰, which signals hiring pressure but is a vendor source.

Comparable company examples were limited in the pack, so the case examples draw mainly on public health and workforce sources.

• Paediatric pulmonologist availability, mean by hospital referral region 0.98pediatric pulmonologists per 100,000 children Observed United States, Later period, earlier and later periods not stated in excerp... [13]

Case examples are chosen from the pack and are not a representative sample of providers.

88. Outlook and strategic implications

The base case is rising demand for respiratory care. COPD cases are projected to grow by 23% globally ⁴, and projected exacerbations rise toward 567.6 million at a later point ⁵. Sleep-related demand is likely to be large but is uncertain in size because OSA estimates vary widely ⁷⁹.

Workforce outcomes are more uncertain. Adequacy projections above 100% at national level ¹¹¹² sit alongside a recruiting signal of strong demand for pulmonologists ¹⁰. The likely shift is toward local and subspecialty shortages, rather than a uniform national gap. This is an interpretation of the pack, not a verified forecast.

Practical implications differ by stakeholder. Providers and health systems should plan for an ageing workforce and for demand that may outpace supply in some areas ¹⁰¹⁴. Funders and payers need reimbursement and cost data, which the pack does not provide. Suppliers and investors lack a verified market size, so decisions should wait for better data. Policymakers can use equity evidence ⁴ to target access, and researchers should address the low certainty of OSA prevalence evidence ⁹.

Outlook uses forecasts and estimates, which are labelled as such in the text.

99. Conclusion

Pulmonology, respiratory and sleep medicine faces a large and growing disease burden, a workforce that is ageing, and access gaps that vary by geography. The most defensible takeaway is that demand is high and rising, but the economic size of the specialty and the capacity of its services cannot yet be measured reliably from the verified evidence.

How this was built

Sources

1. 1

   Burden of chronic respiratory diseases and their attributable risk factors in 204 countries and territories: Results from the global burden of disease study

   Global Burden of Disease Study collaborators (published in a peer-reviewed journal) Peer-reviewed

   mednexus.org
2. 2

   Chronic Respiratory Diseases Affect Nearly 570 Million People Worldwide, Study Finds

   Infection Control Today (news report on a Global Burden of Disease analysis) News report

   infectioncontroltoday.com
3. 3

   Chronic respiratory diseases

   World Health Organization Official statistics

   who.int
4. 4

   Chronic respiratory diseases and health equity: a spotlight on COPD and asthma in the WHO European Region

   WHO Regional Office for Europe, developed with the European Respiratory Society Official statistics

   knowledge-action-portal.com
5. 5

   Forecasting the Global Economic and Health Burden of COPD

   CHEST journal Peer-reviewed

   journal.chestnet.org
6. 6

   The global burden of COPD: epidemiology and effect of prevention strategies

   The Lancet Respiratory Medicine Peer-reviewed

   thelancet.com
7. 7

   Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis

   Benjafield AV, Ayas NT, et al. (Lancet Respiratory Medicine) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
8. 8

   Obstructive sleep apnea prevalence in the elderly meta-analysis (ScienceDirect) and global burden review (PMC)

   Systematic review and meta-analysis in older adults (journal article, ScienceDirect) Peer-reviewed

   sciencedirect.com
9. 9

   Worldwide prevalence and associated risk factors of obstructive sleep apnea: a meta-analysis and meta-regression

   Sleep and Breathing (Springer), Singh et al. Peer-reviewed

   link.springer.com
10. 10

    Physician Supply Considerations: The Emerging Shortage of Medical Specialists (as reported by AASM)

    Merritt Hawkins Associates (physician recruiting firm), reported by American Academy of Sleep Medicine Vendor report

    aasm.org
11. 11

    Cardiologist supply and adequacy projections (Health Workforce Simulation Model), with critical care and pulmonology adequacy

    Peer-reviewed cross-sectional study using HRSA Health Workforce Simulation Model data Peer-reviewed

    pmc.ncbi.nlm.nih.gov
12. 12

    National Center for Health Workforce Analysis physician projections fact sheet

    HRSA National Center for Health Workforce Analysis Official statistics

    bhw.hrsa.gov
13. 13

    Child Health Needs and the Pediatric Pulmonology Workforce

    American Board of Pediatrics Foundation-sponsored supplement (Pediatrics journal) Peer-reviewed

    publications.aap.org
14. 14

    Physician Deserts: Navigating the Texas Terrain of Provider Supply and Demand with GIS Mapping

    Jafri S, Gandhi S, Osei E (Healthcare journal, MDPI) Peer-reviewed

    ncbi.nlm.nih.gov